Compare Ascendis Pharma A/S (ASND) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs JetBlue Airways Corporation — how do they compare? Ascendis Pharma A/S trades at $253.35 (market cap $16.67B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.19B). The key difference: Ascendis Pharma A/S is far larger — about 7.6× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| ASND | JBLU | |
|---|---|---|
Market Cap | $16.67B | $2.19B |
Sector | Health | Industrials |
52-Week High | $277.18 | $6.46 |
52-Week Low | $189.74 | $4.03 |
Enterprise Value | $17.04B | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
JetBlue (JBLU) trades at $5.64, down 7.08% amid a recent analyst downgrade. The stock shows a bullish technical signal with oversold RSI conditions, but fundamentals reveal persistent losses with a -9.32% net margin and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations, yet revenue trends remain volatile, and cash flow from operations turned negative in 2025. The company is implementing strategic fare changes and targeting 2028 profitability.
The outlook is cautious; while cost initiatives and premium product expansions offer long-term potential, high debt levels, fuel cost pressures, and inconsistent earnings pose significant risks. Analyst consensus is mixed with a hold-heavy rating and a $5.18 price target slightly below the current price, reflecting skepticism about near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
